Connect target biology to structure
Map viral proteins to replication, entry, genome processing, polyprotein maturation, or host-interaction roles before evaluating their co-crystal ligand evidence.
Why this page exists
A practical guide to viral protein drug targets
Researchers searching for viral drug targets usually need more than a protein name. They need to know what the target does in the viral life cycle, why it can be inhibited, what structural evidence exists, and whether a bound ligand contains regions that may tolerate chemical modification.
Interpret ligand-bound evidence
Review how inhibitors occupy catalytic motifs, metal-binding sites, nucleotide channels, allosteric pockets, or surface grooves that may affect viral fitness.
Prioritize follow-up questions
Use structure-backed evidence to ask whether a ligand series is suited for optimization, analog comparison, exit-vector analysis, or degrader-oriented exploration.
Target classes
Structurally important viral proteins for antiviral drug discovery
The best viral protein drug targets tend to combine biological necessity, a ligandable structural feature, and enough experimental context to compare inhibitors across related structures.
Proteases Polyprotein processing, viral maturation, active-site inhibition
Viral proteases cleave viral polyproteins into functional proteins required for replication, assembly, and maturation. Because protease active sites often contain conserved catalytic residues and well-defined substrate-recognition pockets, they remain among the most interpretable viral drug targets for structure-guided inhibitor design.
Functional importance
Blocking protease activity can prevent production of mature viral enzymes and structural proteins, disrupting the viral life cycle after translation.
Structural design cues
Co-crystal structures can expose catalytic dyads or triads, covalent-warhead geometry, noncovalent pocket occupancy, flap movement, and conserved hydrogen-bond networks.
V-LiSEMOD questions
Which ligand atoms are buried? Which atoms face solvent? Are key pocket contacts conserved across related viral protease structures?
Polymerases Genome replication, nucleotide analogs, allosteric pockets
Viral RNA-dependent RNA polymerases, DNA polymerases, and polymerase complexes copy viral genetic material. They are attractive because viral replication depends on accurate and efficient genome synthesis, while ligand-bound structures can reveal nucleotide-binding channels, metal coordination, template-primer positioning, and non-nucleoside pockets.
Functional importance
Polymerase inhibition can suppress viral genome replication, reduce production of infectious particles, or interfere with replication complex assembly.
Structural design cues
Structures may show catalytic aspartates, nucleotide analog placement, palm/fingers/thumb domains, RNA-template channels, and resistance-sensitive residue positions.
V-LiSEMOD questions
Does the ligand mimic a nucleotide, occupy an allosteric pocket, or expose a modifiable region away from conserved catalytic machinery?
Reverse transcriptase RNA-to-DNA conversion, NRTI/NNRTI design, resistance context
Reverse transcriptase converts viral RNA into DNA and is central to retroviral replication. Ligand-bound structures can support comparison of nucleoside reverse transcriptase inhibitors, non-nucleoside allosteric inhibitors, RNase H-directed ligands, and resistance-associated binding changes.
Functional importance
Disrupting reverse transcription prevents formation or processing of viral DNA, limiting the ability of retroviruses to establish productive infection.
Structural design cues
Co-crystals can show polymerase-site occupancy, allosteric pocket shape, domain movement, ligand-induced conformations, and mutation-sensitive interactions.
V-LiSEMOD questions
How does a ligand sit relative to conserved polymerase residues, RNase H motifs, or known resistance regions?
Integrase Viral DNA insertion, strand transfer, metal-binding pharmacophores
Viral integrase inserts viral DNA into the host genome. Integrase structures are useful for understanding strand-transfer inhibition, metal-chelating pharmacophores, viral DNA positioning, and interactions that distinguish catalytic-site inhibitors from allosteric or interface-directed ligands.
Functional importance
Inhibiting integration blocks a required step in retroviral replication and can prevent stable insertion of viral genetic material.
Structural design cues
Important features include divalent metal coordination, active-site geometry, DNA-contacting residues, oligomeric state, and ligand orientation within the intasome context.
V-LiSEMOD questions
Which inhibitor atoms coordinate metals or occupy conserved pockets, and which regions remain exposed for analog growth?
Spike, envelope, and fusion proteins Attachment, membrane fusion, entry inhibition, interface pockets
Viral entry proteins mediate receptor engagement, membrane fusion, or envelope remodeling. They can be challenging small-molecule targets because many functional surfaces are large and dynamic, but structurally supported pockets, grooves, fusion intermediates, and ligand-bound conformations can still guide inhibitor discovery.
Functional importance
Blocking entry can prevent the earliest stage of infection by interfering with receptor binding, conformational triggering, or fusion machinery.
Structural design cues
Useful structures may show pocket opening, glycoprotein conformational states, fusion peptide context, receptor-interface contacts, or stabilizing allosteric ligands.
V-LiSEMOD questions
Is the ligand bound to a discrete pocket, a protein-protein interface, a transient groove, or a conformation-specific site?
Helicases and accessory proteins Genome handling, immune modulation, emerging pockets
Viral helicases, methyltransferases, capsid-associated proteins, and accessory proteins can become tractable when structures reveal nucleotide-binding sites, RNA-binding grooves, enzyme active sites, or protein-interaction surfaces. These targets often require careful structural triage because ligandability can vary widely by protein family and conformational state.
Functional importance
These proteins can support replication complex activity, genome unwinding, RNA processing, immune evasion, assembly, or host-pathway manipulation.
Structural design cues
Design-relevant features may include ATP-binding clefts, RNA channels, methyltransferase pockets, capsid interfaces, and conserved accessory-protein interaction hotspots.
V-LiSEMOD questions
Does the available structure show a ligandable pocket with a bound ligand, or only a broad surface that needs more evidence before medicinal chemistry follow-up?
Planned visuals
Infographic slots for viral drug target graphics
Click any graphic to open a full-size readable view. These visuals support the page’s structure-guided target discovery workflow.
Why co-crystal structures matter
What structure-backed ligand data can support
V-LiSEMOD is designed around the idea that a ligand is not just a molecule name. Its value depends on how it sits in a viral protein, which residues it contacts, and which atoms remain accessible for chemistry.
Inhibitor optimization Open design details
Binding pose and interaction evidence help distinguish ligand regions that are likely essential for activity from regions that may tolerate analog growth. For viral drug targets, this is especially important when conserved catalytic motifs or resistance-sensitive residues constrain medicinal chemistry options.
- Identify protected pharmacophores and buried atoms.
- Inspect hydrogen bonds, hydrophobic contacts, ionic interactions, and metal coordination.
- Compare whether analogs preserve key target-class interactions.
Ligand comparison Open comparison details
Cross-structure comparison can reveal whether different ligands exploit the same pocket, avoid the same liabilities, or interact with distinct viral protein subpockets. This can help researchers interpret target-specific series behavior instead of treating all inhibitors as equivalent.
- Compare ligand contacts across PDB structures.
- Separate conserved interactions from structure-specific artifacts.
- Review how related ligands use catalytic, allosteric, or interface-adjacent sites.
Binding pocket analysis Open pocket details
Pocket-level review helps researchers evaluate whether a viral target has a discrete ligandable site, a dynamic cleft, a shallow surface groove, or a structure that may require additional validation before chemistry investment.
- Inspect local residue context around bound ligands.
- Evaluate pocket openness, shape, and possible clash points.
- Use PyMOL-ready exports for deeper structural review.
Warhead selection Open warhead details
For covalent or warhead-oriented follow-up, structure-backed review helps determine whether a reactive group is positioned near a plausible nucleophile and whether nearby ligand atoms remain available for modification without disrupting core binding.
- Review catalytic residues and nearby nucleophilic side chains.
- Distinguish binding-critical atoms from exposed attachment points.
- Use solvent-exposed atom context to form exit-vector hypotheses.
Degrader-readiness triage Open triage details
PROTACability-style review should be framed as hypothesis generation, not proof of degradation feasibility. V-LiSEMOD can help identify viral target-ligand structures where the ligand appears to expose a chemically accessible region that might support linker exploration.
- Prioritize ligand-bound structures with interpretable exit vectors.
- Flag targets where pocket burial may make linker attachment unrealistic.
- Move promising hypotheses into downstream degrader design workflows.
Workflow
How to evaluate a viral drug target in V-LiSEMOD
The page should lead visitors from search intent into action: identify a viral target, inspect available structures, compare ligands, and decide whether follow-up chemistry is reasonable.
-
1
Search by viral protein or virus
Start with a target such as HIV protease, HIV reverse transcriptase, viral integrase, SARS-CoV-2 main protease, a polymerase complex, or an entry-associated glycoprotein.
-
2
Review ligand-bound structures
Inspect available co-crystal structures and determine whether the ligand binding mode supports interpretable inhibitor, analog, or exit-vector analysis.
-
3
Compare contacts and exposed atoms
Use residue interactions, pocket context, and solvent-exposed atom information to distinguish conserved binding features from modifiable ligand regions.
-
4
Export or continue downstream
Move from target exploration into PyMOL review, ligand comparison, warhead-readiness evaluation, or degrader-oriented design workflows when the structural evidence supports it.
FAQ
Viral drug targets and structure-guided antiviral discovery
What are viral drug targets?
Viral drug targets are viral proteins, enzymes, or functional assemblies that can be inhibited to disrupt infection, replication, maturation, immune evasion, or spread. Common examples include proteases, polymerases, reverse transcriptase, integrase, entry proteins, helicases, and selected accessory proteins.
Why are co-crystal ligand structures useful for antiviral drug discovery?
Co-crystal structures show how a ligand binds a viral protein target. They can reveal important pocket contacts, catalytic-site engagement, ligand orientation, buried pharmacophores, solvent-exposed atoms, and structural liabilities that are difficult to infer from a molecule name alone.
Which viral proteins are common antiviral drug targets?
Well-studied viral drug target classes include viral proteases, RNA and DNA polymerases, reverse transcriptase, integrase, entry or fusion proteins, helicases, methyltransferases, capsid proteins, and accessory proteins with structurally defined binding pockets.
Can V-LiSEMOD prove that a viral protein is degradable with a PROTAC?
No. V-LiSEMOD supports PROTACability-style structural triage by highlighting ligand-bound viral targets, solvent-exposed atoms, and possible attachment logic. That information can generate hypotheses, but experimental degradation feasibility depends on cellular localization, target turnover, ternary complex formation, linker behavior, E3 ligase compatibility, and biology beyond the co-crystal structure.
How does V-LiSEMOD help with viral drug target prioritization?
V-LiSEMOD helps users move from a viral protein target to structure-backed ligand evidence. Researchers can inspect binding context, compare ligands, review residue interactions, export visualization-ready files, and decide which targets or ligand series deserve deeper follow-up.
Start exploring
Find viral protein-ligand structures and evaluate target context
Use the target-centric query interface for viral protein drug target exploration, or open the main structure explorer to inspect ligand-bound viral structures directly.